FDA approves daily pill for deadly cancer
The FDA approved a new oral drug, Rasonque, for adults with metastatic pancreatic cancer who have previously received treatment. The medication, developed by Revolution Medicines, targets the RAS protein to inhibit tumor growth and was approved following positive trial results showing median survival nearly doubled compared to standard chemotherapy. The approval was expedited through priority review and breakthrough therapy designation due to the drug’s potential to address an unmet medical need in a disease with a high mortality rate.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)